Page last updated: 2024-11-05

beta-nicotyrine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10249
CHEMBL ID1522291
CHEBI ID7564
SCHEMBL ID2996756
MeSH IDM0052609

Synonyms (56)

Synonym
pyridine, 3-(1-methylpyrrol-2-yl)-
nsc127943
1-methyl-2-(3-pyridyl)pyrrole
3-(1-methyl-2-pyrrolyl)pyridine
pyridine, 3-(1-methyl-1h-pyrrol-2-yl)-
3,2'-nicotyrine
nsc-127943
.beta.-nicotyrine
pyridine, 3-(1-methyl-2-pyrrolyl)-
ai3-11314
3-(1-methyl-1h-pyrrol-2-yl)pyridine
nsc 127943
brn 0121347
einecs 207-651-1
3-(1-methylpyrrol-2-yl)pyridine
NSC407276 ,
nsc-407276
487-19-4
nicotyrine
beta-nicotyrine
NCGC00163362-01
nsc 407276
|a-nicotyrine
CHEMBL1522291
chebi:7564 ,
AKOS006280935
3-(1-methyl-1h-pyrrol-2-yl)-pyridine
unii-xn4r1lh79y
xn4r1lh79y ,
2-(1-methyl-2-pyrryl)pyridine
3-(1-methyl-1h-pyrrole-2-yl)-pyridine
1-methyl-2-(3-pyridyl) pyrrole
FT-0622929
nicotine resinate impurity b [ep impurity]
nicotine ditartrate dihydrate impurity b [ep impurity]
nicotine impurity b [ep impurity]
bdbm109750
us8609708, 19 ?-nicotyrine
us8609708, 19 beta-nicotyrine
SCHEMBL2996756
b-nicotyrine
W-106043
DTXSID3075048
nicotine ditartrate dihydrate impurity b (ep impurity)
nicotine resinate impurity b (ep impurity)
nicotine impurity b (ep impurity)
3-(1-methyl-1h-pyrrol-2-yl)pyridine (beta-nicotyrine)
nycotrine
Z1198153878
-nicotyrine
Q1987338
ss-nicotyrine
(3-(1-methyl-1h-pyrrol-2-yl)pyridine
beta -nicotyrine
EN300-309080
F78093
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.62280.011212.4002100.0000AID1030
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)2.20000.00011.753610.0000AID1622671
Cytochrome P450 2A6Homo sapiens (human)IC50 (µMol)2.20000.00443.889510.0000AID1622671
Cytochrome P450 2A6Homo sapiens (human)Ki7.50000.00561.52717.5000AID1209284
Cytochrome P450 2A13Homo sapiens (human)Ki5.60000.04002.71005.6000AID1209283
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2A6Homo sapiens (human)Kd71.00000.68003.19506.2000AID1209278
Cytochrome P450 2A13Homo sapiens (human)Kd8.20000.43003.18008.2000AID1209287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A6Homo sapiens (human)
steroid metabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin catabolic processCytochrome P450 2A6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A13Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 2A13Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A13Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A13Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 2A6Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A6Homo sapiens (human)
enzyme bindingCytochrome P450 2A6Homo sapiens (human)
heme bindingCytochrome P450 2A6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A6Homo sapiens (human)
monooxygenase activityCytochrome P450 2A13Homo sapiens (human)
iron ion bindingCytochrome P450 2A13Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A13Homo sapiens (human)
heme bindingCytochrome P450 2A13Homo sapiens (human)
aromatase activityCytochrome P450 2A13Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A13Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A13Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A6Homo sapiens (human)
cytoplasmic microtubuleCytochrome P450 2A6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A6Homo sapiens (human)
cytoplasmCytochrome P450 2A6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A13Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A13Homo sapiens (human)
cytoplasmCytochrome P450 2A13Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1209278Binding affinity to CYP2A6 (unknown origin) assessed as type 1 interaction as increase in absorbance 379 to 387 nm and decrease in 414 to 420 nm2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.
AID1209285Ratio of Ki for CYP2A6 (unknown origin) to Ki for CYP2A13 (unknown origin)2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.
AID589225Mechanism based inhibition of human cytochrome P450 2A6 measured by coumarin 7-hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1209283Mixed inhibition of CYP2A13 (unknown origin)2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.
AID1209287Binding affinity to CYP2A13 (unknown origin) assessed as type 1 interaction as increase in absorbance 379 to 387 nm and decrease in 414 to 420 nm2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.
AID1209284Mixed inhibition of CYP2A6 (unknown origin)2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.
AID1209280Ratio of Kd for CYP2A6 (unknown origin) to Kd for CYP2A13 assessed as type 1 interaction as increase in absorbance 379 to 387 nm and decrease in 414 to 420 nm2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's1 (20.00)24.3611
2020's3 (60.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.83 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]